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AbstrACt
Introduction Patients with chronic atrophic gastritis (CAG) 
and intestinal metaplasia (IM) are at risk of developing 
gastric adenocarcinoma. Their diagnosis and management 
currently rely on histopathological guidance after random 
endoscopic biopsy sampling (Sydney biopsy strategy). This 
approach has significant flaws such as under-diagnosis, 
poor reproducibility and poor correlation between 
endoscopy and histology. This prospective, international 
multicentre study aims to establish whether endoscopy-
led risk stratification accurately and reproducibly predicts 
CAG and IM extent and disease stage.
Methods and analysis Patients with CAG and/or 
IM on standard white light endoscopy (WLE) will be 
prospectively identified and invited to undergo a second 
endoscopy performed by an expert endoscopist using 
enhanced endoscopic imaging techniques with virtual 
chromoendoscopy. Extent of CAG/IM will be endoscopically 
staged with enhanced imaging and compared with standard 
WLE. Histopathological risk stratification through targeted 
biopsies will be compared with endoscopic disease staging 
and to random biopsy staging on WLE as a reference. At 
least 234 patients are required to show a 10 % difference 
in sensitivity and accuracy between enhanced imaging 
endoscopy-led staging and the current biopsy-led staging 
protocol of gastric atrophy with a power (beta) of 80 % and a 
0.05 probability of a type I error (alpha).
Ethics and dissemination The study was approved by the 
respective Institutional Review Boards (Netherlands: MEC-
2018-078; UK: 19/LO/0089). The findings will be published in 
peer-reviewed journals and presented at scientific meetings.
trial registration number NTR7661; Pre-results.
IntroduCtIon
Gastric adenocarcinoma remains a major 
cause of cancer mortality and is the most 
commonly diagnosed malignant condition 
of the gastrointestinal (GI) tract.1–4 Although 
incidence rates had previously been declining, 
recent studies demonstrated this differs 
among population subgroups. For example, 
an increasing incidence of gastric adenocarci-
noma among young white cohorts in Western 
countries was objectified. This may be due 
to an increasing prevalence of gastric cancer 
precursors among younger adults, in partic-
ular chronic atrophic gastritis (CAG), intes-
tinal metaplasia (IM) and dysplasia.5 6 These 
studies suggest that gastric cancer incidence 
rates may plateau or even increase again in 
the upcoming years. Importantly, with the 
exception of Japan and Korea, the majority 
of gastric cancers worldwide are diagnosed at 
later stage. This results in a poor prognosis 
with less than 30% 5 year survival.1 2 7 Japan’s 
strengths and limitations of this study
 ► This is the first study to compare endoscopy-led risk 
stratification of premalignant gastric lesions using 
advanced imaging and targeted biopsies with white 
light endoscopy and random biopsies as a reference, 
performed at separate occasions with the endosco-
pist blinded to prior results.
 ► This study will additionally provide biobank biopsy 
and serum material for future biomarker analysis.
 ► A possible limitation of this study is that all proce-
dures will be performed by expert endoscopists in 
teaching hospitals, therefore external reproducibility 
will be evaluated using interobserver variability of 
disease staging through video recordings.
 ► The same limitation holds for the histopathological 
evaluation of the biopsy samples for which a pro-
portion of the samples will be reviewed and re-
scored by a blinded second expert gastrointestinal 
histopathologist.
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earlier stage of diagnosis and superior 5 year survival high-
light the need for earlier recognition and treatment.8
Endoscopic recognition of the premalignant stomach 
has long been problematic and limited by the ability 
of endoscopist and the imaging tools. A previous study 
demonstrated that 22% of high-grade dysplastic lesions 
and early gastric cancers were missed.9 10 A meta-anal-
ysis and systematic review of endoscopy follow-up studies 
confirmed that a marked proportion of early gastric 
cancers are missed at endoscopy.10 Therefore, current 
practice uses histology-based staging.11 12 However, 
endoscopic imaging has significantly improved with 
high-definition endoscopes and imaging enhancement 
technologies now routinely available. Some recent 
studies already suggested that accurate endoscopic 
staging of CAG and gastric intestinal metaplasia (GIM) 
is achievable and can robustly predict gastric adenocar-
cinoma risk. Importantly, the interobserver and intraob-
server reproducibility characteristics of endoscopic CAG 
and GIM severity assessment are in experienced hands 
moderate to excellent.13–18 These marked improvements 
in endoscopic technology and the shift towards an endos-
copy-led approach will empower the endoscopist to risk 
stratify individuals with greater accuracy and decrease the 
already huge burden placed on our endoscopy and histo-
pathology departments. Therefore, the aim of this study 
is to evaluate if enhanced endoscopic imaging, including 
high-definition white light endoscopy (WLE) and virtual 
chromoendoscopy, alongside targeted biopsies, provides 
an accurate and reproducible assessment of CAG and 
IM disease extent and staging, when compared with the 
current practice of WLE and random biopsies through 
the Sydney protocol biopsy strategy.
MEthods And AnAlysIs
Aims
The primary aim of this study is to assess the diagnostic accu-
racy for the endoscopic diagnosis of IM in Sydney biopsy loca-
tions comparing standard endoscopic staging with random 
biopsies with enhanced imaging with biopsies targeted to 
GIM.19 The Standards for Reporting of Diagnostic Accuracy 
Studies (STARD) guidelines were followed.20 Study sites are 
located in the Netherlands and the UK. Secondary objec-
tives are to evaluate (a) reproducibility of endoscopic staging 
after expert review, (b) reproducibility of histopathology for 
detection of IM, (c) the number of dysplastic or neoplastic 
lesions detected and (d) effects of inspection time of gastric 
mucosa on diagnostic accuracy.
design
This is a prospective, multicentre registry study on the 
accuracy and reproducibility of enhanced endoscopic 
imaging, including high-definition WLE and virtual 
chromoendoscopy, for the staging of CAG and IM. Two 
upper endoscopies will be performed on two separate 
occasions (6–12 months in between) using standard 
white-light endoscopy plus random biopsies (current 
diagnostic strategy) at the first endoscopy and enhanced 
endoscopic imaging with targeted biopsies (proposed 
diagnostic strategy) at the second endoscopy. We will 
compare both approaches using histopathology as a 
reference and assess the accuracy and reproducibility 
of enhanced endoscopic imaging (figure 1).
PAtIEnt And PublIC InvolvEMEnt
We maintained close links with patient alliances and interest 
groups, both in the Netherlands as well as in the UK. This 
close relationship informs our practice and is the basis for 
the current study design. We will engage closely with patient 
interest groups to communicate research findings and 
ensure that our deliverables are fit for purpose.
PArtICIPAnts
sample size
For estimation of sample size, we assume that the diagnosis 
of CAG or IM on enhanced imaging and targeted biopsies 
must be set with at least a 90% sensitivity with WLE and 
random biopsies as a reference.15 A power (beta) of 80% 
and a probability of type I error (alpha) of 0.05 will be 
handled. That purpose requires at least 234 patients to be 
recruited to show a 10 % difference in sensitivity between 
enhanced endoscopy-led staging and the standard WLE.
recruitment
All patients (>18 years of age) referred to the endoscopy 
department for routine diagnostic upper GI endoscopy 
and diagnosed with CAG or IM between November 
2018 and June 2020 are eligible for inclusion if able 
to give informed consent. Patients are excluded when 
having (1) gastric neoplasia not amenable to endo-
scopic resection, (2) no indication for Sydney biopsy 
staging on standard WLE, (3) significant comorbidity, 
(4) a coagulation disorder, (5) previous gastric surgery 
or (6) are unable to complete the biopsy protocol in 
either endoscopy session.
IntErvEntIons
baseline characteristics
All patients are asked to complete a questionnaire on life-
style factors, medical history, past interventions, medica-
tion use and family history of gastric cancer.
White light endoscopy
Patients referred to the endoscopy department for upper 
GI endoscopy for investigation of symptoms or for surveil-
lance of a known condition will undergo their proce-
dure on a standard diagnostic gastroscopy list. Patients 
found to have CAG or IM will be prospectively identified. 
During the initial procedure, patients will receive the 
current recommended practice. Current practice is to 
initially identify if gastric atrophy is present and to inspect 
the gastric mucosa for areas suspicious for dysplasia or 
malignancy. Any mucosal abnormalities suspicious for 
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Figure 1 Flowchart of the study design. CAG, chronic atrophic gastritis; EGGIM, endoscopic grading of gastric intestinal 
metaplasia; GI, gastrointestinal; H. pylori, Helicobacter pylori; OLGA, operative link for gastritis assessment; OLGIM, operative 
link for gastric intestinal metaplasia assessment; WLE, white light endoscopy.
Figure 2 Biopsy strategy. (A) Sydney protocol biopsy sites 
in the opened stomach along the greater curvature; (B) 
biopsy sites in the anatomical view.
Table 1 Simplified endoscopic gastric intestinal metaplasia 
staging system: ‘GRAHAM Score’
Focal/minimal 
metaplasia
(<1/3 of surface 
coverage)
Moderate/
extensive 
metaplasia
(>1/3 surface 
coverage)
Antrum and 
incisura
1 2
Lesser curve 1 2
Greater curve 1 2
dysplasia or malignancy are biopsied with tissue biopsies 
placed in separate containers. Following this, 10 random 
biopsies are taken according to the Sydney protocol (see 
also figure 2): 4 quadrant biopsies of the antrum, 2 biop-
sies from the incisura and 4 biopsies from the body of the 
stomach, respectively, 2 from the lesser curve, and 2 from 
the greater curve.
Enhanced imaging endoscopy
Patients who opt to be recruited to the study will be invited 
for a second endoscopy at 6–12 months interval. This will 
be performed by one of the experts on this protocol. The 
endoscopists will be blinded to any previous endoscopy 
or biopsy results. This second endoscopy will be recorded 
and performed using enhanced endoscopic imaging. 
Given that these patients will have recently undergone a 
complete upper GI endoscopy, while all anatomical land-
marks will be viewed, the focus of this examination will be 
on the gastric mucosa. The endoscopist will record (1) 
the extent of gastric atrophy, (2) the presence and extent 
of IM in each of the aforementioned areas. This will be 
done using our simplified endoscopic metaplasia scoring 
system (GRAHAM Score) (table 1).
Biopsies will then be taken in the following manner: (1) 
areas of IM found in any of the Sydney protocol areas, (2) 
Sydney areas negative for GIM will be randomly biopsied, 
as control, to complete the assessment and (3) lesions 
suspicious for dysplasia or malignancy.
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histopathological assessment
Each biopsy will be reviewed at the teaching hospital by one 
of the expert GI histopathologists named on this protocol 
according to the established operative link for gastritis 
assessment and operative link for gastric intestinal meta-
plasia assessment staging systems.21 Histopathologists will 
be blinded to whether biopsies were directed at areas suspi-
cious for IM and to the biopsy results of WLE staging. A 
proportion of biopsy samples will be reviewed and rescored 
by a second expert GI histopathologist, who is blinded to 
the initial results. This is to ensure interobserver reproduc-
ibility for histopathological detection of IM.
serology assessment
A proportion of the collected serum will be used to assess 
Helicobacter pylori serology, pepsinogen I/II ratio and 
gastrin-17. The remaining serum will then be stored for 
use in future studies exploring the development of molec-
ular biomarkers for gastric atrophy risk stratification.
data collection and management
All data collected for this study will be recorded in an anony-
mised format on a centralised, secure web-based platform 
(OpenClinica). Source data will be recorded in patients’ 
notes or electronic health records, and hard copies of 
consent forms will be stored in a secure locked cabinet per 
site. All study data will be stored in a linked anonymised 
fashion against a study number, with the registry of study 
numbers stored separately on an encrypted database.
statistical analyses
For descriptive statistics, mean (±SD) will be used in 
case of a normal distribution of variables and median 
(25–75%) will be used for variables with a skewed distri-
bution. Where appropriate, the Student’s t-test or Mann–
Whitney U test will be used.
Diagnostic accuracy of endoscopic diagnosis of CAG 
and IM is defined as the total number of directed biop-
sies that confirm the endoscopic impression of the pres-
ence or absence of IM divided by the total number of 
biopsies (accuracy=true positives+true negatives/all biop-
sies). Results will be compared with the histopathology 
outcomes using the χ2 test after multiple testing correc-
tion as well as kappa values for interobserver agreement 
among endoscopists and histopathologists.
After study completion, all videos will be collated and 
anonymised prior to expert panel review and estimation 
of the severity and extent of atrophy as well as IM. Five 
expert reviewers will review 50 videos each (kappa 0.4) 
for the purposes of assessing interobserver reliability. 
Sensitivity, specificity and global accuracy along with the 
95% confidence intervals will be established. Duration of 
inspection time of gastric mucosa and its relation to diag-
nostic accuracy will be evaluated using, when appropriate, 
a paired t-test or Wilcoxon test. All tests will be two-sided.
Ethics and dissemination
Results will be disseminated to potential users in academia 
and medical industries, through the standard routes of 
presentations, oral and posters, at local, national and inter-
national conferences, undergraduate and graduate teaching 
and through peer-reviewed publication. Efforts will be made 
to present work in a timely manner at key international 
meetings to encourage collaboration with research partners.
dIsCussIon
The recently updated European MAnagement of Precan-
cerous conditions and lesions in the Stomach (MAPS) 
guidelines recommend surveillance of patients with prema-
lignant gastric mucosal lesions by performing endoscopy 
(preferably with advanced imaging) and taking random 
biopsies of the stomach for histopathological assessment. 
This enables the detection of progression to high-risk 
lesions and eventually cancer.22 However, various studies 
indicate that a marked proportion of advanced gastric 
lesions are missed at a stage when these lesions are poten-
tially still amenable to endoscopic management. This 
implies that the risk of undertreatment is undeniable.9 
The development of high-definition endoscopy and virtual 
chromoendoscopy has been a main focus of research in the 
past years and it has revolutionised the endoscopic assess-
ment of the premalignant stomach by being superior to 
white light imaging.23 The updated MAPS guidelines opt 
for the use of advanced imaging as the preferred surveil-
lance method. Recently, Esposito et al showed a scoring tool 
based on endoscopic staging using Endoscopic Grading 
of Gastric Intestinal Metaplasia (EGGIM) with advanced 
imaging as a promising decision tool to identify patients 
at risk of gastric cancer.24 However, currently there are no 
studies on how the use of advanced endoscopic imaging to 
detect IM of the stomach can be applied in countries with 
a low prevalence of IM. Still, histological confirmation is 
needed through random biopsies. Future steps are to eval-
uate the possible shift towards an endoscopy-led strategy 
now these marked improvements in endoscopic technology 
are within our reach. This prospective study was therefore 
designed to determine the validity of endoscopy-led staging 
of the premalignant stomach using advanced imaging and 
taking targeted biopsies for histological confirmation.
A previous comparative study between white light and 
high-definition endoscopy for the diagnosis of premalig-
nant gastric lesions indeed showed a superior diagnostic 
accuracy of high-definition endoscopy.15 However, one 
limitation was that WLE and high-definition endoscopy 
were performed during one occasion, which implied 
that the endoscopist was not blinded to the WLE results. 
Within the current protocol, we choose to perform the 
procedures on two separate occasions with blinding of 
the expert endoscopist to the previous WLE results.
Over the years, serological markers have shown major 
promise for predicting the presence and severity of gastric 
premalignant lesions.25–27 Pepsinogens are serological 
markers for atrophy in the stomach and can be divided into 
pepsinogen I and II. A decreased PG I/II ratio indicates 
the presence of atrophic changes. Gastrin serum levels are 
indicative for gastric acid output and are increased in the 
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presence of atrophic changes.27 The collection of serum 
samples was included in our protocol to strengthen risk 
stratification for progression of premalignant gastric lesions.
A few limitations of the study should be mentioned. 
All high-definition endoscopies will be performed by 
expert endoscopists at either site. A potential caveat with 
this design is the generalisability of the study outcomes 
to non-expert settings. To test this, we selected a panel 
of independent endoscopists who will review recorded 
endoscopy videos in order to assess interobserver vari-
ability. The same limitation holds for the histopatho-
logical evaluation of the biopsy samples. Therefore, a 
proportion of the samples will be reviewed and rescored 
by a blinded second expert GI histopathologist.
In conclusion, prospective validation of endoscopy-led 
staging of the premalignant stomach will provide the needed 
evidence for an endoscopy-led risk stratification of patients 
at risk for gastric adenocarcinoma. This will allow rational 
design of tiered screening and surveillance protocols to 
benefit early stage gastric cancer detection within at-risk 
populations. This will cause major implications for affected 
patients and general healthcare resource utilisation.
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